CA2372511A1 - Polypeptides secretes et transmembranaires et acides nucleiques les codant - Google Patents

Polypeptides secretes et transmembranaires et acides nucleiques les codant Download PDF

Info

Publication number
CA2372511A1
CA2372511A1 CA002372511A CA2372511A CA2372511A1 CA 2372511 A1 CA2372511 A1 CA 2372511A1 CA 002372511 A CA002372511 A CA 002372511A CA 2372511 A CA2372511 A CA 2372511A CA 2372511 A1 CA2372511 A1 CA 2372511A1
Authority
CA
Canada
Prior art keywords
seq
polypeptide
cell
acid sequence
fgfr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002372511A
Other languages
English (en)
Other versions
CA2372511C (fr
Inventor
Avi J. Ashkenazi
Kevin P. Baker
David Botstein
Luc Desnoyers
Dan L. Eaton
Napoleone Ferrara
Sherman Fong
Wei-Qiang Gao
Hanspeter Gerber
Mary E. Gerritsen
Audrey Goddard
Paul J. Godowski
Austin L. Gurney
Ivar J. Kljavin
Jennie P. Mather
Mary A. Napier
James Pan
Nicholas F. Paoni
Margaret Ann Roy
Timothy A. Stewart
Daniel Tumas
Colin K. Watanabe
P. Mickey Williams
William I. Wood
Zemin Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1999/020111 external-priority patent/WO2000012708A2/fr
Priority claimed from PCT/US1999/020594 external-priority patent/WO2000015666A2/fr
Priority claimed from PCT/US1999/021090 external-priority patent/WO2000015796A2/fr
Priority claimed from PCT/US1999/021547 external-priority patent/WO2000015797A2/fr
Priority claimed from PCT/US1999/028313 external-priority patent/WO2000032221A2/fr
Priority claimed from PCT/US1999/028301 external-priority patent/WO2000032776A2/fr
Priority claimed from PCT/US1999/028565 external-priority patent/WO2000037638A2/fr
Priority claimed from PCT/US2000/000219 external-priority patent/WO2000053753A2/fr
Priority claimed from PCT/US2000/004342 external-priority patent/WO2000078961A1/fr
Priority claimed from PCT/US2000/004341 external-priority patent/WO2000053756A2/fr
Priority claimed from PCT/US2000/004414 external-priority patent/WO2001004311A1/fr
Priority claimed from PCT/US2000/005601 external-priority patent/WO2000056889A2/fr
Priority claimed from PCT/US2000/005841 external-priority patent/WO2000053758A2/fr
Priority claimed from PCT/US2000/007377 external-priority patent/WO2001019991A1/fr
Priority claimed from PCT/US2000/008439 external-priority patent/WO2000073454A1/fr
Priority claimed from PCT/US2000/013358 external-priority patent/WO2000075317A2/fr
Priority claimed from PCT/US2000/013705 external-priority patent/WO2000073445A2/fr
Application filed by Individual filed Critical Individual
Publication of CA2372511A1 publication Critical patent/CA2372511A1/fr
Application granted granted Critical
Publication of CA2372511C publication Critical patent/CA2372511C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Urology & Nephrology (AREA)

Abstract

L'invention concerne des nouveaux polypeptides ainsi que des molécules d'acides nucléiques codant ces polypeptides. Elle concerne encore des vecteurs et des cellules hôtes comprenant ces séquences d'acides nucléiques, des molécules polypeptidiques chimères comprenant les polypeptides de l'invention fusionnés à des séquences polypeptides hétérologues, des anticorps se liant aux polypeptides de l'invention, ainsi que des procédés de production desdits polypeptides.
CA2372511A 1999-06-15 2000-05-22 Polypeptides secretes et transmembranaires et acides nucleiques les codant Expired - Lifetime CA2372511C (fr)

Applications Claiming Priority (45)

Application Number Priority Date Filing Date Title
US13969599P 1999-06-15 1999-06-15
US60/139,695 1999-06-15
US14507099P 1999-07-20 1999-07-20
US60/145,070 1999-07-20
US14569899P 1999-07-26 1999-07-26
US60/145,698 1999-07-26
US14939699P 1999-08-17 1999-08-17
US60/149,396 1999-08-17
PCT/US1999/020111 WO2000012708A2 (fr) 1998-09-01 1999-09-01 Nouveaux pro-polypeptides et sequences correspondantes
USPCT/US99/20111 1999-09-01
PCT/US1999/020594 WO2000015666A2 (fr) 1998-09-10 1999-09-08 Compositions et methodes de traitement des tumeurs
USPCT/US99/20594 1999-09-08
USPCT/US99/21547 1999-09-15
PCT/US1999/021090 WO2000015796A2 (fr) 1998-09-16 1999-09-15 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
PCT/US1999/021547 WO2000015797A2 (fr) 1998-09-17 1999-09-15 Compositions et methodes de traitement des maladies relatives au syteme immunitaire
USPCT/US99/21090 1999-09-15
USPCT/US99/28313 1999-11-30
PCT/US1999/028313 WO2000032221A2 (fr) 1998-12-01 1999-11-30 Promotion et inhibition de l'angiogenese et de la vascularisation cardiaque
PCT/US1999/028301 WO2000032776A2 (fr) 1998-12-01 1999-12-01 Polypeptides secretes et transmembranaires et acides nucleiques les codant
USPCT/US99/28301 1999-12-01
PCT/US1999/028565 WO2000037638A2 (fr) 1998-12-22 1999-12-02 Methodes permettant d'inhiber la croissance de cellules neoplasiques
USPCT/US99/28565 1999-12-02
US16949599P 1999-12-07 1999-12-07
US60/169,495 1999-12-07
USPCT/US00/00219 2000-01-05
PCT/US2000/000219 WO2000053753A2 (fr) 1999-03-08 2000-01-05 Activation ou inhibition de l'angiogenese et de la cardiovascularisation
PCT/US2000/004341 WO2000053756A2 (fr) 1999-03-08 2000-02-18 Polypeptides secretes et transmembranaires et acides nucleiques codant ces polypeptides
USPCT/US00/04342 2000-02-18
PCT/US2000/004342 WO2000078961A1 (fr) 1999-06-23 2000-02-18 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
USPCT/US00/04341 2000-02-18
PCT/US2000/004414 WO2001004311A1 (fr) 1999-07-07 2000-02-22 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
USPCT/US00/04414 2000-02-22
USPCT/US00/05601 2000-03-01
PCT/US2000/005601 WO2000056889A2 (fr) 1999-03-23 2000-03-01 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci
USPCT/US00/05841 2000-03-02
PCT/US2000/005841 WO2000053758A2 (fr) 1999-03-08 2000-03-02 Compositions et methodes de traitement des maladies immunitaires
USPCT/US00/07377 2000-03-20
PCT/US2000/007377 WO2001019991A1 (fr) 1999-09-15 2000-03-20 Compositions et techniques permettant de traiter des maladies d'origine immunologique
USPCT/US00/08439 2000-03-30
PCT/US2000/008439 WO2000073454A1 (fr) 1999-06-02 2000-03-30 Polypeptides transmembranaires secretes et acides nucleiques codants pour ceux-ci
USPCT/US00/13358 2000-05-15
PCT/US2000/013358 WO2000075317A2 (fr) 1999-06-09 2000-05-15 Compositions et methodes de traitement de tumeur
USPCT/US00/13705 2000-05-17
PCT/US2000/013705 WO2000073445A2 (fr) 1999-06-02 2000-05-17 Promotion ou inhibition de l'angiogenese et de la cardiovascularisation
PCT/US2000/014042 WO2000077037A2 (fr) 1999-06-15 2000-05-22 Polypeptides secretes et transmembranaires et acides nucleiques les codant

Publications (2)

Publication Number Publication Date
CA2372511A1 true CA2372511A1 (fr) 2000-12-21
CA2372511C CA2372511C (fr) 2011-11-22

Family

ID=36028885

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2372511A Expired - Lifetime CA2372511C (fr) 1999-06-15 2000-05-22 Polypeptides secretes et transmembranaires et acides nucleiques les codant

Country Status (5)

Country Link
EP (1) EP1208195A2 (fr)
JP (6) JP2003529324A (fr)
AT (2) ATE449109T1 (fr)
CA (1) CA2372511C (fr)
WO (1) WO2000077037A2 (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773252A (en) 1995-06-05 1998-06-30 Human Genome Sciences, Inc. Fibroblast growth factor 15
WO2002008288A2 (fr) * 2000-07-20 2002-01-31 Genentech, Inc. Polypeptides secretes et transmembranaires et acides nucleiques codant ces polypeptides
US6506569B1 (en) 1997-05-30 2003-01-14 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor TR10
US6551799B2 (en) 1999-12-07 2003-04-22 Genentech, Inc. Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
WO2002016611A2 (fr) * 2000-08-24 2002-02-28 Genentech, Inc. Polypeptides d'interleukine-22, acides nucleiques codant pour lesdits polypeptides et methode permettant de traiter les affections pancreatiques
US20030190669A1 (en) * 1998-12-30 2003-10-09 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
ATE396201T1 (de) * 1999-03-23 2008-06-15 Genentech Inc Ausgeschiedene und transmembranpolypeptide und dafür kodierende nukleinsäure
US7307161B1 (en) 1999-04-28 2007-12-11 Genetics Institute, Llc Human Gil-19/AE289 polynucleotides
US6939545B2 (en) 1999-04-28 2005-09-06 Genetics Institute, Llc Composition and method for treating inflammatory disorders
JP3964678B2 (ja) 1999-10-28 2007-08-22 アジェンシス，インコーポレイテッド ３６ｐ６ｄ５：分泌腫瘍抗原
EP1234035B1 (fr) 1999-12-03 2010-02-24 ZymoGenetics, Inc. Recepteur de cytokine humaine
US7226591B2 (en) 2000-05-22 2007-06-05 Genentech, Inc. Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
US20030170823A1 (en) 1999-12-23 2003-09-11 Presnell Scott R. Novel cytokine ZCYTO18
ATE355305T1 (de) * 1999-12-23 2006-03-15 Kirin Brewery Verfahren und materialien bezüglich stammzell wachstumsfaktor ähnlichen polypeptiden und polynukleotiden
AU6531101A (en) * 2000-06-02 2001-12-17 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030012788A1 (en) 2000-07-27 2003-01-16 Jean-Christophe Renauld Method for influencing kinase pathways with IL-22
WO2002010217A2 (fr) 2000-08-02 2002-02-07 The Johns Hopkins University Profils d'expression de cellules endotheliales
AU2001290524A1 (en) 2000-08-08 2002-02-18 Zymogenetics Inc. Soluble zcytor 11 cytokine receptors
JP2004518425A (ja) * 2000-12-23 2004-06-24 麒麟麦酒株式会社 幹細胞成長因子様ポリペプチドおよびポリヌクレオチドに関連した方法および物質
WO2002064769A1 (fr) * 2001-02-15 2002-08-22 Shionogi & Co., Ltd. Nouveau marqueur de maladies
US7638604B2 (en) 2001-02-23 2009-12-29 Genetics Institute, Llc Monoclonal antibodies against interleukin-22
AU2002308251A1 (en) * 2001-03-13 2002-09-24 Bayer Aktiengesellschaft Human prenylcysteine lyase-like protein
AU2002252460A1 (en) 2001-03-27 2002-10-08 Zymogenetics, Inc. Human cytokine receptor
EP1578981A4 (fr) * 2001-05-25 2006-06-21 Amgen Inc Molecules de marqueur endothelial tumoral 7alpha et utilisations associees
WO2003013580A1 (fr) * 2001-08-03 2003-02-20 Genset S.A. Traitement des troubles du metabolisme a l'aide d'agonistes et d'antagonistes xidatine
US20030219823A1 (en) * 2001-09-07 2003-11-27 Alsobrook John P. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7205275B2 (en) 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US20050084841A1 (en) * 2002-01-29 2005-04-21 Orit Segev Isle gene and its association with osteoarthritis and other bone and cartilage disorders expression products derived therefrom and uses thereof
JP4504023B2 (ja) 2002-03-22 2010-07-14 ザイモジェネティクス インコーポレーティッド 抗ｉｌ−ｔｉｆ抗体および炎症において使用する方法
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
JP2007525437A (ja) 2003-03-24 2007-09-06 ザイモジェネティクス， インコーポレイテッド 抗ｉｌ−２０抗体および結合パートナーならびに炎症において用いる方法
KR20170119737A (ko) 2003-05-06 2017-10-27 가부시키가이샤 니콘 투영 광학계, 노광 장치 및 노광 방법
US7348575B2 (en) 2003-05-06 2008-03-25 Nikon Corporation Projection optical system, exposure apparatus, and exposure method
JP2007520217A (ja) * 2004-01-27 2007-07-26 コンピュゲン ユーエスエイ，インク． 新規ヌクレオチドおよびアミノ酸配列、ならびにそれを用いた乳癌診断のためのアッセイおよび使用方法
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
JP2008505182A (ja) 2004-07-02 2008-02-21 ジェネンテック・インコーポレーテッド 非ホジキンリンパ腫の治療のための組成物と方法
EP1781824A2 (fr) * 2004-08-25 2007-05-09 Genentech, Inc. Nouvelles disruptions geniques; compositions et methodes y relatives
AU2005299809B2 (en) 2004-10-22 2010-12-02 Zymogenetics, Inc. Anti-IL-22RA antibodies and binding partners and methods of using in inflammation
EP1790664A1 (fr) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Anticorps monoclonaux contre claudin-18 pour le traitement du cancer
TW200744634A (en) 2006-02-21 2007-12-16 Wyeth Corp Methods of using antibodies against human IL-22
TWI417301B (zh) 2006-02-21 2013-12-01 Wyeth Corp 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
WO2013167153A1 (fr) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Anticorps utiles dans le diagnostic du cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5707829A (en) * 1995-08-11 1998-01-13 Genetics Institute, Inc. DNA sequences and secreted proteins encoded thereby
US5824504A (en) * 1996-09-26 1998-10-20 Elshourbagy; Nabil A. Human 7-transmembrane receptor and DNA
US6057435A (en) * 1997-09-19 2000-05-02 Genentech, Inc. Tie ligand homologues
ATE447583T1 (de) * 1997-09-17 2009-11-15 Genentech Inc Polypeptide und dafür kodierende nukleinsäure
AU4320499A (en) * 1998-06-02 1999-12-20 Eli Lilly And Company Angiopoietin related gene sequence scarface 1
EP1037915A1 (fr) * 1998-10-09 2000-09-27 Incyte Pharmaceuticals, Inc. Genes de remodelage de matrice

Also Published As

Publication number Publication date
ATE448246T1 (de) 2009-11-15
CA2372511C (fr) 2011-11-22
JP2006061156A (ja) 2006-03-09
JP2003529324A (ja) 2003-10-07
EP1208195A2 (fr) 2002-05-29
JP2006051032A (ja) 2006-02-23
JP2006051031A (ja) 2006-02-23
JP2006068006A (ja) 2006-03-16
WO2000077037A2 (fr) 2000-12-21
ATE449109T1 (de) 2009-12-15
JP2006025795A (ja) 2006-02-02
WO2000077037A3 (fr) 2002-02-28

Similar Documents

Publication Publication Date Title
CA2372511A1 (fr) Polypeptides secretes et transmembranaires et acides nucleiques les codant
CN101704879B (zh) 具有改进的特异性的新型免疫球蛋白结合蛋白
EP0640135B1 (fr) Proteines fixatrices de l'immunoglobuline derivees de la proteine l et leurs utilisations
CA2505705A1 (fr) Compositions et methodes pour le diagnostic et le traitement d'une tumeur
CA2383424A1 (fr) Nouvelles molecules b7-4 et leurs utilisations
CA2309783A1 (fr) Facteur de croissance des fibroblastes 19
CN102791726A (zh) 纯化免疫球蛋白溶液的方法
RU2003103099A (ru) Интерферон-подобный белок zcyto21
CN101128586A (zh) 制备可溶性多跨膜蛋白的方法
JPWO2006004067A1 (ja) ブレビバチルス属細菌を用いたプロテインａ様蛋白質の生産方法
WO2006084388A1 (fr) Muteines de streptavidine monomeres
EP1114161B1 (fr) Proteine de liaison de l'immunoglobuline
JP2022511718A (ja) 抗Ｔａｑ ＤＮＡポリメラーゼ抗体及びその用途
Harrison et al. Factors affecting the fermentative production of a lysozyme‐binding antibody fragment in Escherichia coli
CA2347649A1 (fr) Gene et proteine mn
CN104066745A (zh) 溶菌酶作为标签的用途
CN113777295A (zh) 用于检测肿瘤标志物pd-l1的高灵敏度量子点探针、制备方法及应用
US20220033484A1 (en) Antibody against human cardiac troponin I and use thereof
US8586315B2 (en) Fluorescent protein particles
CN111925425B (zh) 甲胎蛋白特异性结合多肽及应用
CN113621079A (zh) Fab抗体与小牛肠碱性磷酸酶的融合蛋白及其制备方法
RU2007141407A (ru) Композиции и способы, которые можно использовать для диагностики и лечения опухолей
CN113087807B (zh) 用于检测糖类抗原的基于志贺毒素b亚基重组蛋白的探针、制备方法
CA2669951A1 (fr) Particules proteiques
CN109880840A (zh) 一种重组蛋白大肠杆菌体内生物素化标记系统

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20200522